4D Molecular Therapeutics, Inc. Common Stock

FDMT XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

480M

Short interest (May 15)

23.1%

Net Short (Jun 03 ): -0.1%

Borrow Fee

0.40%

↓ 0.1%

Available Shares

600K

↑ 2.2%

Price Chart

Company Overview

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001650648

Asset Type: CS

Market Data

Market Cap: $484,600,874

Employees: 196

Status: Active

Short Interest

Current Borrow Fee 0.40%

Range: 0.40% - 0.42%

Available Shares 600K

Range: 600K - 650K

Recent Changes

Fee Change: ↑ 2.3%

Available Change: ↑ 4.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime